Reimbursement decisions are rarely driven by evidence alone. They are shaped by the interaction between clinical value, budget realities, operational constraints and institutional risk tolerance. Fyrn Perspectives explores the strategic dynamics behind these decisions across global healthcare systems.
Explore our expert perspectives on healthcare market access, reimbursement strategies, and evidence-based approaches shaping life sciences decision-making globally.
Understanding the hidden system dynamics shaping NHS reimbursement decisions. Strong clinical evidence and favourable cost-effectiveness models do not automatically translate into reimbursement. Many technologies fail not because the evidence is weak, but because it does not align with how payer systems actually make decisions.
How launch sequencing shapes global pricing power. Global pricing power is often determined long before negotiations begin. The order in which markets evaluate and reimburse a technology can quietly shape the pricing corridor available across multiple healthcare systems.
Why cost-effective technologies still struggle to diffuse. A technology can be cost-effective on paper yet still struggle to diffuse in practice. Adoption decisions are often shaped less by economic value and more by operational realities such as service capacity, workflow disruption and short-term budget pressures.
